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non-health resources utilization under routine medical practice
derived in substantial costs when treating refractory painful due
to cervical or lumbar radiculopathy. About two-thirds of the
total costs were derived from non-health resources.
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OBJECTIVES: To analyze the Pregabalin (PGB) effect under
routine medical practice on longitudinal health and non-health
resources utilization (HRU) and derived costs of treating refrac-
tory painful Radiculopathy in Primary Care Setting (PCS) during
12-weeks. METHODS: A representative sample of PC centres
included men and women above 18 years, with chronic pain
(6-month or more) due to cervical (17%) or lumbar (83%)
radiculopathy refractory to, at least, one previous analgesic [mean
(SD) number of drugs; 2.6 (1.4)], in a prospective, naturalistic,
12-weeks two-visit study. Health resources included all-type
medical visits, hospitalizations, complementary test and pharma-
cological and non-pharmacological therapies. Non-health
included wages loses due to loss-work-days equivalents
(LWDE = absenteeism days + days working with reduced produc-
tivity due to pain). Pain severity was measured by McGill-pain
scale. Descriptive statistics and ANCOVA models were applied
to compare 12-weeks periods of treatment. RESULTS: One-
thousand-three-hundred-ﬁfty-one PGB-naive patients [55.8%
women, 56.7 (12.5) years] were analyzed: 490 (36%) switched to
PGB as monotherapy (PGBm), 702 (52%) patients received PGB
as add-on therapy (PGBadd-on), and in 159 (12%) previous
treatment was replaced by a regimen not including PGB (Non-
PGB). As compared to non-PGB, both PGBm and PGBadd-on
showed signiﬁcantly higher HRU reduction. The extra costs of
drugs, particularly in PGB subgroups [€15.4 (39.1), €148.6
(109.1) and €145.3 (119.6), respectively (p < 0.0001 within and
between groups)] was off-set by higher signiﬁcant reductions in all
other components of health costs (except non-pharmacological
therapies in non-PGB group) yielding to a greater total cost
reductions: €1203.3 (1805.6), €1423.2 (1650.0) and €1429.2
(1966.2), respectively (p < 0.001 within and p = 0.0004 between
groups). CONCLUSION: In the primary care setting either
add-on or monotherapy with pregabalin under routine medical
practicewas associatedwith a signiﬁcant longitudinal reduction in
HRU and total costs when compared with non-PGB therapy in
subjects with painful radiculopathy of cervical or lumbar origin.
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OBJECTIVES: To analyze health and non-health resources utili-
zation and derived costs of treating patients with refractory
peripheral NeP followed in PCS under routine medical practice.
METHODS: A 12-weeks cross-sectional and retrospective analy-
sis was carried out in year 2006 in a whole-nation representative
sample of PC centres. Men and women above 18 years, with
chronic pain (6-month or more) due to peripheral NeP (diabetic
neuropathy, post-herpetic neuralgia or trigeminal neuralgia), and
refractory to, at least, one previous analgesic were included in the
analysis. Health resources included all-type medical visits, hos-
pitalizations, complementary test and pharmacological and non-
pharmacological therapies. Non-health included wages loses due
to loss-work-days equivalents (LWDE = absenteeism days + days
working with reduced productivity due to pain). Pain severity
was measured by McGill-pain scale. RESULTS: One-thousand-
four-hundred-thirty-nine subjects [58.8% women, 59.5 (12.7)
years] were analyzed: 783 (54%) with diabetic painful neuropa-
thy (DPN), 486 (34%) with post-herpetic neuralgia (PHN), and
170 (12%) with trigeminal neuralgia (TN). Last-week mean pain
severity was 70.8 (16.1) mm with 60.2% declaring the pain as
severe or worst the day of collecting data. Previous mean (SD)
number of drugs was 2.3 (1.3), with a 30.3% on one-drug only;
72% on NSAIDs, 43% on paracetamol, 36% on opiods, 23% on
antiepileptics, and 11% on antidepressants. Quarterly mean
LWDE was 37.5 (27.6) days. Medical visits average per trimester
was 9.7 (7.6), with 4.4% declaring one-hospitalization. Quar-
terly total mean cost was €2689 (2236); €983 (1394) direct
health cost and €1706 (1440) indirect cost. Cost and health
resources utilization were not associated to aetiological cause of
pain. CONCLUSION: In the primary care setting, health and
non-health resources utilization under routine medical practice
derived in substantial costs when treating the associated refrac-
tory pain to peripheral neuropathies due to diabetes, post-
herpetic or trigeminal neuralgia. Two-thirds of the total costs
were derived from non-health resources.
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OBJECTIVES: In this prospective study, we captured resource
utilization and work productivity due to breakthrough pain
(BTP). METHODS: The sample consisted of outpatients at a
large U.S. academic medical center who had chronic pain due to
headache, musculoskeletal problems, arthritis/rheumatism, and
sickle cell anemia. Patients were administered a 1-week diary
which captured demographics, disability, pain (10-point VAS),
resource utilization due to BTP (hospitalizations, emergency
room visits, outpatient visits, and calls to physician ofﬁces), and
work productivity (Health-Related Productivity Questionnaire-
Diary). RESULTS: Among the 161 patients enrolled, 142
reported at least 1 BTP ﬂare during the diary week (90.5%). Of
these, 36 suffered from chronic headache (25.3%), 16 from
arthritis/rheumatism (11.3%), 16 from sickle cell anemia
(11.3%), 9 from musculoskeletal problems (6.3%), and 1 from
neuropathy (0.7%). The remainder reported 2 or more painful
conditions (45.1%; n = 64). The cohort experienced 2561 BTP
ﬂares (mean per patient per week = 18). Mean pain levels were
5.3 for headache, 5.2 for arthritis/rheumatism, 6.2 for sickle cell
anemia, 6.8 for musculoskeleletal problems, and 6 for those with
2 or more painful conditions. BTP ﬂares resulted in 8 hospital-
izations, 9 emergency room visits, 30 outpatient medical visits,
and 24 calls to physician ofﬁces during the diary week and
Abstracts A465
participants missed a total of 191 work hours due to BTP
(mean = 1.9 work hours lost per participant). Many were unable
to work due to disability (n = 45; 31.7%) and disability was
more common in patients with 2 or more painful conditions
(p = 0.004). Anxiety and depression were noted to be prevalent
(22.5% reported anxiety, 24.6% reported depression, 16.2%
reported both), particularly among those with headache alone or
2 or more painful conditions (p = 0.035). CONCLUSION:
Patients with BTP frequently seek care to control their pain and
also experience productivity loss. Anxiety and depression may
add to the economic burden of BTP.
PAIN—Health Care Use & Policy Studies
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OBJECTIVES: To examine the use of extended release (ER)
opioids relative to immediate release (IR) opioids in chronic
opioid treatment episodes. METHODS: Data from the i3
Innovus Lab/Rx Database were used in this analysis. Enrollees
having at least one pharmacy claim for a combination opioid,
extended release opioid or immediate release opioid between
June-2003 and May-2006 and having at least one year of con-
tinuous enrollment beyond the date of their ﬁrst observed opioid
pharmacy claim were included in this analysis. Opioid-related
treatment episodes were created by combining contiguous days
of therapy allowing for a maximum of a 7-day gap between
medication reﬁlls. Opioid-containing preparations were classiﬁed
as either ER or IR formulations. Outcomes are reported in the
form of probabilities and odds-ratios. RESULTS: A total of
3,993,011 opioid treatment episodes were derived from
1,967,898 patients. Overall, treatment episodes involving IR
preparations (97.7%) are more prevalent than treatment epi-
sodes using ER preparations (2.3%). The odds of an ER pre-
paration being prescribed chronically (> = 60 days) was
approximately 11 times that of an IR preparation, OR = 10.7.
The data were further stratiﬁed by prescriber-type (designated as
pain specialist or non-specialist). The probability of a pain spe-
cialist prescribing ER opioids in these chronic episodes was
19.1%; whereas the probability for non-specialists was 13.7%.
In comparing the two prescriber groups, pain specialists are
about 50% more likely to prescribe ER opioids relative to non-
specialists, OR = 1.49. CONCLUSION: These data suggest that
clinical practice does not follow accepted pain treatment guide-
lines for chronic pain. Further research will need to be conducted
to better understand physician prescribing behaviors as they
relate to chronic pain treatment and why the existence of treat-
ment guidelines may not alone be sufﬁcient to promote a medi-
cation regimen that will optimize pain care for appropriate
patients.
PAIN—Methods and Concepts
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OBJECTIVES: To understand how patients with chronic non-
cancer pain deﬁne and describe breakthrough pain (BTP).
METHODS: This prospective study included outpatients from a
large U.S. tertiary medical center who suffer from chronic pain
due to headache, arthritis/rheumatism, musculoskeletal prob-
lems, or sickle cell anemia. Data were collected using a 1-week
pain diary with questionnaire that captured their perceptions of
BTP. Participants were asked to choose a term that best describes
a pain ﬂare and a deﬁnition of the term they selected. Pain scores
were captured using a 10-point visual analog scale (VAS).
RESULTS: The study cohort included 161 patients (36 with
headache, 19 with arthritis/rheumatism, 17 with sickle cell
anemia, 8 with musculoskeletal problems, and 70 with 2 pain
conditions). Most were female (80.1%), white (67.7%), and
experienced BTP during the diary week (90.5%). The mean pain
level reported during the diary week was 6, and the mean age was
49.3 years. The terms used to describe BTP were “pain ﬂare”
(34%), “acute pain episode” (29.1%), “pain crisis” (19.9%),
“sudden new pain episode” (16.5%), and “breakthrough pain”
(11.9%). There were no differences by pain source except among
headache patients, where more than half (52.8%) termed BTP as
“an acute pain episode.” Most commonly selected deﬁnitions for
BTP were “sudden pain more than your chronic pain” (31.3%),
“a period of pain worse than your controlled pain” (26%) and
“a brief episode of pain more intense than your usual pain”
(21.3%). There were no differences in preferred BTP deﬁnition
by pain source. CONCLUSION: Patients with chronic pain
prefer to use the terms “pain ﬂare” and “acute pain episode”
rather than “breakthrough pain” when referring to BTP. The
concepts of “brief” and “sudden” appear to be important when
deﬁning BTP. Results will be helpful to outcomes researchers
who study pain.
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OBJECTIVES: To achieve a linguistic adaptation and psycho-
metric validation into Spanish of the ID Pain questionnaire for
the screening of differential diagnosis of pain with a neuropathic
component. METHODS: Cross-sectional validation study
carried out in two phases: cultural adaptation into Spanish lan-
guage and validation study to test psychometric properties of the
scale in men and women >18 years, with neuropathic (NP) and
noniceptive (NNP) chronic pain for more than 6 months. Scale
properties of feasibility, reliability and validity were evaluated
according to clinical and LANNS scale reference diagnosis.
Factor and ROC curves analysis, agreement with reference diag-
nosis and determination of sensitivity and speciﬁcity values were
assessed. RESULTS: A total of 283 subjects (64.4% women;
mean age: 59.1 + 14.9 years), 145 (51.2%) with NP and 138
(48.8%) with NNP were included in the study. Time to comple-
tion of questionnaire was 4.2 (3.0) minutes, and 15% of patients
needed some help to complete it only. Factor analysis showed a
one-dimension scale only, explaining the 37.5% of total variance.
The instrument was time-stable (test-retest r-Pearson = 0.98,
p < 0.0005). Mean score differentiated NP from NNP patients;
3.5 (1.2) vs. 1.2 (1.4); p < 0.0005. Optimum cut-off value was >3
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